GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » EBIT

Inari Medical (Inari Medical) EBIT : $-10.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inari Medical EBIT?

Inari Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-16.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Inari Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -10.15%. Inari Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -55.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Inari Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -0.36%.


Inari Medical EBIT Historical Data

The historical data trend for Inari Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical EBIT Chart

Inari Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -0.27 14.92 10.98 -25.89 4.44

Inari Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.15 3.07 5.63 -3.11 -16.01

Competitive Comparison of Inari Medical's EBIT

For the Medical Devices subindustry, Inari Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inari Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inari Medical's EV-to-EBIT falls into.



Inari Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inari Medical  (NAS:NARI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Inari Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-32.38 * ( 1 - -50.44% )/( (484.136 + 476.156)/ 2 )
=-48.712472/480.146
=-10.15 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=674.235 - 74.647 - ( 115.452 - max(0, 76.339 - 235.563+115.452))
=484.136

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=661.776 - 84.318 - ( 101.302 - max(0, 86.037 - 233.313+101.302))
=476.156

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Inari Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-64.036/( ( (69.336 + max(45.464, 0)) + (68.371 + max(47.693, 0)) )/ 2 )
=-64.036/( ( 114.8 + 116.064 )/ 2 )
=-64.036/115.432
=-55.48 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(70.119 + 42.9 + 7.092) - (74.647 + 0 + 0)
=45.464

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(78.621 + 44.65 + 8.74) - (84.318 + 0 + 1.4210854715202E-14)
=47.693

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Inari Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-10.413/2854.539
=-0.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inari Medical EBIT Related Terms

Thank you for viewing the detailed overview of Inari Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Inari Medical (Inari Medical) Business Description

Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism. The company generates revenue from the sale of ClotTriever and FlowTriever systems directly to hospitals located in the United States. Majority of revenue is generated from FlowTriever system.
Executives
William Hoffman director, officer: President and CEO C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill, officer: Chief Financial Officer 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Andrew Hykes officer: Chief Operating Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Thomas Tu officer: Chief Medical Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Donald B Milder director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Rebecca Chambers director 3052 ORCHARD DR., SAN JOSE CA 95134
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a. 10 percent owner NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v. 10 percent owner NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB

Inari Medical (Inari Medical) Headlines